|
|
Volumn 96, Issue 17, 2004, Pages 1268-1270
|
|
Medicare cost containment strategy targets several oncology drugs
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BEVACIZUMAB;
CETUXIMAB;
DOCETAXEL;
GOSERELIN;
IRINOTECAN;
LEUPRORELIN;
NAVELBINE;
PACLITAXEL;
RITUXIMAB;
TRASTUZUMAB;
ZOLEDRONIC ACID;
ADVANCED CANCER;
CANCER CHEMOTHERAPY;
CANCER SURVIVAL;
COLON CANCER;
COLORECTAL CANCER;
COMMUNITY CARE;
COST BENEFIT ANALYSIS;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG INDUSTRY;
GOVERNMENT;
HEALTH CARE COST;
HEALTH CARE DELIVERY;
HUMAN;
MEDICAL DECISION MAKING;
MEDICAL SPECIALIST;
MEDICARE;
MEDICOLEGAL ASPECT;
NOTE;
ONCOLOGY;
PATIENT CARE;
PRIORITY JOURNAL;
PRIVATE PRACTICE;
PROSTATE CANCER;
REIMBURSEMENT;
ARTICLE;
ECONOMICS;
FEE;
UNITED STATES;
ANTINEOPLASTIC AGENTS;
COST CONTROL;
COST-BENEFIT ANALYSIS;
DRUG COSTS;
HUMANS;
MEDICARE;
PRESCRIPTION FEES;
REIMBURSEMENT MECHANISMS;
UNITED STATES;
|
|
EID: 4444349836
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/96.17.1268 Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|